# Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment

> **NCT05119738** · — · UNKNOWN · sponsor: **Pontificia Universidad Catolica de Chile** · enrollment: 122 (estimated)

## Conditions studied

- Sars-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** Three doses of BNT162b2 (observational)
- **BIOLOGICAL:** Two doses of Coronavac and one dose BNT162b2 (observational)

## Key facts

- **NCT ID:** NCT05119738
- **Lead sponsor:** Pontificia Universidad Catolica de Chile
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-27
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2022-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05119738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05119738, "Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05119738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*